DAB2IP expression is high in almost all normal mucosa (92/100); while it markedly goes down to about 37.7% (61/162) in CRC in situ and about 19.4% (12/62) in metastatic lesions, which suggests that DAB2IP may serve as a basis for CRC occurrence and progression (Fig. 1D). This evidence concerns the gene DAB2IP and colorectal carcinoma.